Navigation Links
Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
Date:8/7/2012

SAN FRANCISCO, Aug. 7, 2012 /PRNewswire/ -- Adynxx, a clinical stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today the completion of enrollment in the Phase 1 clinical study in healthy volunteers of its lead investigational drug candidate for the prevention of acute and chronic post-surgical pain, AYX1.

"The Adynxx therapeutic platform – a novel approach to treating and preventing pain – has the potential to transform pain management," said Dennis Podlesak, chairman of the Adynxx board of directors. "The clinical development of this breakthrough technology is being driven by an accomplished management team that has a track record of success that includes building successful biotech companies and attaining multiple new drug approvals. The Adynxx team is well positioned to achieve our goal of developing these exciting new treatment options for preventing pain."

The 30 subject, dose-escalating study is currently evaluating AYX1 in five cohorts of healthy volunteers. Later this year, Adynxx plans to move into a proof-of-concept Phase 2 clinical study assessing the ability of a single administration of AYX1 at the time of surgery to reduce acute pain, prevent the transition to persistent post-surgical pain and consequently improve functional recovery.

"Despite many years of investigation and development, effective relief of post-surgical pain remains a challenge for the millions of patients who undergo surgery every year," said Rick Orr, president and chief executive officer of Adynxx. "Given the urgent need for new treatment options for post-surgical pain, we are excited to have advanced the AYX1 development program at such a rapid pace since the company's founding.  With enrollment complete, we look forward to receiving and evaluating the unblinded safety data later this quarter.  This will allow us to initiate a Phase 2 efficacy study in the coming months."

Added Donald C. Manning, M.D., Ph.D., chief medical officer of Adynxx, "Therapeutics currently available to physicians and patients address pain as a symptom and often only as it arises. While we believe that these established therapeutics have a place in treatment of pain, we are interested in developing transformative options for those who seek to treat pain as a preventable and ultimately curable disease."

The AYX therapeutic platform was designed by Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx, to specifically address a significant unmet need in pain therapy: providing long-term pain relief with a one-time treatment. It acts by simultaneously neutralizing complementary and redundant molecular mechanisms that maintain pain over time.  Long-term efficacy of AYX1 after a single administration has been demonstrated in a variety of preclinical pain and functional assessment models.  In addition to AYX1, Adynxx is advancing a pipeline of therapeutics for treatment of other indications, including chronic lower back pain and intractable neuropathic and inflammatory pain syndromes.

About Adynxx

Adynxx, located in San Francisco, California, is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom. 

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery.  Adynxx has completed enrollment in a Phase 1 clinical trial of AYX1 and plans to initiate a Phase 2 study of AYX1 in Q4 2012.  AYX2, intended to resolve multiple forms of chronic lower back pain, is currently in pre-clinical development along with additional compounds intended to target a range of intractable neuropathic and inflammatory pain syndromes. For more information, visit www.adynxx.com

Media Contact:

David Schull or Ian Stone
Russo Partners
(858) 717-2310
(619) 308-6541
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Acquisition Of World Heart Corporation
2. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
3. Hologic Completes Acquisition Of Gen-Probe
4. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
5. United Seating & Mobility Completes Acquisition of Active American Mobility
6. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
7. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
8. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
9. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
10. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
11. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):